Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
ALX Oncology Inc.
University Medical Center Ho Chi Minh City (UMC)
Virginia Commonwealth University
National Cancer Institute (NCI)
Pfizer
Fundació d'investigació Sanità ria de les Illes Balears
Toros University
National Institutes of Health Clinical Center (CC)
Pfizer
Merck Sharp & Dohme LLC
Pfizer
University College, London
Compass Therapeutics
Aurigene Discovery Technologies Limited
Aurigene Discovery Technologies Limited
Pheon Therapeutics
Emory University
University Hospital, Rouen
Eli Lilly and Company
University of Pittsburgh
Incyte Corporation
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
M.D. Anderson Cancer Center
Kestrel Therapeutics, Inc.
BigHat Biosciences, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of California, Irvine
West China Hospital
Ohio State University Comprehensive Cancer Center
Revolution Medicines, Inc.
Celal Bayar University
Memorial Sloan Kettering Cancer Center
Pfizer
Seagen Inc.
Alliance for Clinical Trials in Oncology
Zhongnan Hospital
National Institutes of Health Clinical Center (CC)
Korea University Anam Hospital
Maltepe University
Turning Point Therapeutics, Inc.
Eastern Cooperative Oncology Group
Alterome Therapeutics, Inc.
NRG Oncology
NRG Oncology